For research and educational purposes only. Not medical advice.
Tesofensine Reference
Educational, not medical advice reference for Tesofensine: Fat Loss, Metabolic; regulatory status, evidence posture, source review, and schedule notes. Also…
Reference summary
Phase 2 obesity trials reported substantial weight loss; later development was paused. pepSmart displays tesofensine only as trial-context educational content.
- Categories
- Fat Loss, Metabolic
- Aliases
- NS2330, Triple monoamine reuptake inhibitor, Non-peptide small molecule
- Evidence posture
- human — Human Phase 2 obesity data exist, but tesofensine remains investigational and is not FDA-approved. Cardiovascular and psychiatric adverse-event signals contributed to development delays.
- Regulatory status
- Investigational. Tesofensine is a non-peptide small-molecule monoamine reuptake inhibitor studied for weight loss in obesity, originally developed for Parkinson's and Alzheimer's. There is no FDA-approved tesofensine drug label.
- Content review status
- investigational verified